BeiGene provides grant to Crossroads4Hope to fund psychosocial support programs for cancer patients and communities in NJ

BeiGene, a global, science-driven biotechnology company focused on developing innovative and affordable medicines, and Crossroads4Hope, A Network of Cancer Support, a non-profit organization committed to transforming the cancer experience for patients and their families across New Jersey, has announced a grant from BeiGene that will enable Crossroads4Hope to expand the reach of its psychosocial support programs to more vulnerable patients and communities.
“As BeiGene expands its presence in the New Jersey business community with our new site to be built in Hopewell, we are committed to joining with organizations that are deeply engaged in the New Jersey cancer community, as is Crossroads4Hope,” said Shreya Jani, Vice President of Corporate Affairs at BeiGene. “Crossroads4Hope’s founding belief that all those affected by cancer should have a safe place to turn for emotional and social support, and their commitment to reaching the most vulnerable communities, align well with BeiGene’s vision to change how cancer is treated by developing impactful medicines that will be affordable and accessible to far more cancer patients.”  
Crossroads4Hope provides social and emotional support to those impacted by cancer across communities in New Jersey, including people with cancer, survivors, loved ones, caregivers, and bereaved families. Programs and services are offered at no charge for individuals and families impacted by a cancer diagnosis either directly or indirectly through a loved one. The grant from BeiGene will enable Crossroads4Hope to expand the reach of its services to additional vulnerable communities in New Jersey.

“Crossroads4Hope welcomes BeiGene to New Jersey,” said Amy J. Sutton, CEO at Crossroads4Hope. “We are proud to be a part of this important moment in their corporate history and look forward to a partnership that highlights our mutual commitment to transforming the cancer experience for patients and families.”

BeiGene is expanding its U.S. presence to include a flagship clinical R&D and manufacturing site at the Princeton West Innovation Campus in Hopewell, N.J. This innovation center will support BeiGene’s commitment to advancing life-changing medicines for people living with cancer around the world through state-of-the-art commercial-stage biologic pharmaceutical manufacturing, late-stage research, and clinical development capabilities.

If you rely on MercerMe for your local news, please support us!

This site uses Akismet to reduce spam. Learn how your comment data is processed.